We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Image Analysis Software Manages High-Content Data

By Biotechdaily staff writers
Posted on 12 Feb 2007
A new technology platform provides tools to manage complex three-dimensional (3D) and 4D data, enabling deeper insights into cell biology.

On the occasion of the High Content Analysis Conference, held in San Francisco, CA, USA, in January 2007, Definiens AG (Munich, Germany) recently announced its development strategy for its high-content image analysis application, Definiens Cellenger. More...
Cellenger is built using the open standards-based Definiens Cognition Network Technology, which provides the power and performance required to build a new generation of cognitive applications. Similar to the human mind, Definiens Cognition Network Technology uses objects' color, shape, and size, as well as their specific context and relationships, to understand how cells work.
Current state-of-the-art high-content analysis software provides data based on two dimensional images.

Advances in Definiens' technology will enable research on cell-based assays not currently feasible. The technology strategy focuses on developing a tool box that will enable general purpose 3D and 4D image analysis. Tracking of cells in 3D over time (i.e., 4D) provides useful data regarding cell morphology and structure, including correlating cell speed changes and persistence of movement. With 3D and 4D capability, the analysis of cellular processes over time will be possible, a ground-breaking improvement compared to static and flat snapshots provided by 2D. The analysis of such data, however, presents major challenges for automated image analysis systems; data volume for a single image can easily reach gigabyte levels, for example.

Definiens Cellenger is a flexible and platform-independent enterprise system designed to automate and standardize cell image analysis customized to specific assays. It creates much deeper insights into image data, while providing a simple yet flexible environment to support and accelerate the drug development process. The system integrates within any Definiens Enterprise Image Intelligence product and complements all workflows, whether they be assay development, screening, or informatics. It is the first platform independent high-content analysis software, bridging the gaps between different vendors and platforms, enabling standardization of assays across the enterprise.

Definiens Cellenger contains highly robust detection and classification algorithms that provide accurate multi-dimensional segmentation of objects, even with heterogeneous cell populations or imperfect images that were taken under poor conditions. Multiple image analysis studies can be performed in parallel and export data can be configured to contain the results of one experiment conditional to the results of another, resulting in much higher data confidence levels.

Built on the unique, patented Definiens Cognition Network Technology, Cellenger enables organizations to go beyond the simple measurement of objects by shape and intensity to the quantification of complex relationships between objects, revealing subtle biologic effects. Cellenger has open interfaces and formats and is designed to integrate within existing infrastructures, complementing rather than replacing existing investments in software and hardware.

The system analyzes and interprets images on every scale, from microscopic cell structures to satellite images. Definiens' technology also helps pharmaceutical companies to improve safety and reduce risk, attrition, and time-to-market in the drug development process. It enables organizations to analyze and correlate image information along the entire drug development chain, supporting strategic initiatives such as translational science. As a research and development tool, it identifies more candidates, increasing quality while reducing costs. It vastly simplifies assay development and substantially increases the yield of pertinent information. In the pre-clinical phase, this technology delivers faster results with greater consistency at lower cost. It automates pre-screening, providing consistent, qualified, and quantified information from cell and tissue images.




Related Links:
Definiens

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Varicella Zoster Test
ZEUS ELISA Varicella Zoster IgG Test System
New
Giardia Assay
AccuDiag Giardia
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Switching to an experimental drug after liquid biopsy detection of breast cancer recurrence can improve outcomes (Photo courtesy of Shutterstock)

Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients

Standard treatment for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype driven by estrogen receptors that fuel tumor growth, often involves aromatase inhibitors,... Read more

Pathology

view channel
Image: A new at-home self-collection device aims to reduce the screening gap for cervical cancer (Photo courtesy of CU School of Medicine)

New At-Home Cervical Cancer Screening Device to Increase Accessibility for Patients

Cervical cancer is typically linked to certain types of human papillomavirus (HPV), which is passed through sexual contact. While many people are infected with HPV, only a small percentage will develop... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.